Modified Laparoscopic Transcystic Biliary Drainage in the Management of Cholecystocholedocholithiasis
Launched by PEKING UNIVERSITY THIRD HOSPITAL · Aug 22, 2023
Trial Information
Current as of July 12, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new method for treating patients with gallbladder stones and bile duct stones, a condition known as cholecystocholedocholithiasis. The researchers have developed a modified technique using a special catheter that aims to make it easier and safer to drain bile from the bile duct. This method not only helps with immediate treatment but also allows for easier follow-up care if any stones are left behind after surgery.
To participate in this study, you need to be at least 18 years old and have gallbladder stones along with possible bile duct stones. However, people who already have a drainage system in place, are pregnant, or have certain health concerns may not be eligible. If you choose to join the trial, you can expect to receive care using this new technique, which could potentially lead to better outcomes for managing your condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients ≥ 18 years of age;
- • Patients with gallbladder stones and known or expected concomitant bile duct stones;
- • Informed consent.
- Exclusion Criteria:
- • Biliary drainage is already present, e.g. preoperative ENBD, PTCD;
- • Women who are pregnant;
- • Declined consent;
- • Inability to follow the procedures of the study, e.g. due to language problems and psychological disorders of the participant;
- • Morbid obesity (BMI \> 40);
- • IV-VI class of the American Society of Anesthesiologists physical status classification;
- • Contraindications for general anesthesia or surgery.
About Peking University Third Hospital
Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, None Selected, China
Patients applied
Trial Officials
LINGFU ZHANG
Study Chair
北京大学第三医院
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported